Related Experiment Video
Updated: May 17, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Biomarker-Driven Management of Nonmetastatic GEJ Adenocarcinoma
Hideo Takahashi1,2, Ahmed Dehal3, Haejin In4
1Department of Surgery, Mount Sinai South Nassau, Oceanside, NY, USA.
Background:
Advances in understanding the molecular landscape of gastroesophageal junction (GEJ) adenocarcinoma underscore the need for biomarker-driven treatment approaches.
Materials And Methods:
The Society of Surgical Oncology (SSO) Gastrointestinal (GI) Disease Site Working Group has developed practice guidelines for the biomarker-based management of nonmetastatic GEJ adenocarcinoma, with specific integration of microsatellite instability (MSI) status.
Results:
Although multimodal therapy has improved outcomes, treatment strategies for GEJ adenocarcinoma remain largely stage-based rather than biomarker-directed. With emerging evidence supporting the prognostic and predictive roles of MSI-high (MSI-H), human epidermal growth factor receptor 2 (HER2), and other novel targets, there is an urgent need for clear guidance on how to incorporate biomarkers into the management of resectable disease.
Conclusions:
These guidelines provide evidence-based recommendations to support precision oncology in GEJ cancer care.
